Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Dyadic International ( (DYAI) ) has shared an announcement.
On July 2, 2025, Dyadic International announced a strategic rebranding to ‘Dyadic Applied BioSolutions,’ effective in 30 days, reflecting its shift from a research-driven organization to a commercially focused enterprise. This rebranding underscores the company’s emphasis on commercializing non-therapeutic proteins using its C1 and Dapibus™ platforms, aiming for faster revenue generation and broader market reach. Recent milestones, such as a $250,000 payment for a non-animal dairy enzyme program and a $1.5 million installment from the Gates Foundation, highlight Dyadic’s progress in commercial execution and its strategic focus on market readiness.
The most recent analyst rating on (DYAI) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Dyadic International stock, see the DYAI Stock Forecast page.
Spark’s Take on DYAI Stock
According to Spark, TipRanks’ AI Analyst, DYAI is a Neutral.
Dyadic International’s overall score reflects significant financial challenges, notably ongoing losses and negative cash flows. While strategic partnerships and revenue growth are positive, they are offset by high leverage and operational inefficiencies. The stock’s technical indicators suggest weak momentum, and its valuation remains unattractive due to unprofitability. The earnings call provides some optimism about future growth, but near-term challenges persist.
To see Spark’s full report on DYAI stock, click here.
More about Dyadic International
Dyadic Applied BioSolutions, formerly known as Dyadic International, Inc., is a global biotechnology company focused on the scalable production of high-value, precision-engineered input proteins for non-therapeutic applications in life sciences, food and nutrition, and industrial biotechnology. The company utilizes proprietary gene expression platforms, including the C1 Expression System and Dapibus™, to deliver innovative solutions without the regulatory complexity and high costs associated with therapeutic biologics.
Average Trading Volume: 37,502
Technical Sentiment Signal: Sell
Current Market Cap: $29.19M
See more data about DYAI stock on TipRanks’ Stock Analysis page.